Quality Systems

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

The EU medicines agencies’ network strategy, EMANS, is an update of the five-year strategy previously developed to cover the period 2021 to 2025.

EMA and HMA Publish Joint Network Strategy to 2028

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments, in an interview with Pharmaceutical Technology®.

Industry Outlook 2025: US Political Motivations and Legislative Discussions

In an interview with Pharmaceutical Technology®, Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.

Industry Outlook 2025: Consolidating Data and Relaxing Regulations on AI

Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.

EMA Recommends Four Medicines for Approval in February

The agency has received certification with the Eco-Management and Audit Scheme for its commitment to environmental sustainability.

EMA Earns EMAS Certification

Cheryl Barton is director of PharmaVision, 

EMA introduced its New Fee Regulation in January 2025, but what impact will the new fees and charges have on medicine developers? 

Introducing a New Legal Framework, Fees, and Charges

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

European Drug Shortage Monitoring Platform Fully Operational

The agency’s newly issued letter to Sanofi amends one sent in December 2024, and stems from inspections at its Massachusetts drug manufacturing facility in June and July 2024.

FDA Warns Sanofi About API CGMP Deviations, Issues Clinical Hold on Atara Immunotherapies

Pharmaceutical Technology® spoke with Charles Ruban, president and CEO, Verdot, about the focus of moving to sustainability practices in pharmaceutical manufacturing.

Sustainability in Pharmaceutical Manufacturing

The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.

Regulatory Oversight